 |
|||||
last updated on: May 21, 2013
|
|
||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
| Homepage > Centers |
 |
The Centers
Boston University Cardiovascular Proteomics Center |
||
 |
Catherine E. Costello, Ph.D. |
The Boston University Cardiovascular Proteomics Center (CPC) is a research center funded by the NIH/NHLBI to analyze and identify proteins that may be modified or created by cardiovascular disease (CVD) brought on by unfavorable metabolic conditions and diseases, including obesity, diabetes, and hyperlipidemia. The CPC is developing and applying a targeted proteomic approach and bioinformatics tools to detect the effects of abnormal metabolism on proteins. The identification of a set of markers of metabolic dysfunction may afford opportunities to be used as tissue-specific biomarkers of the disease. These will provide new and powerful approaches to the detection and monitoring of metabolic CVD.
|
Johns Hopkins University Proteomic Innovation Center in Heart Failure |
||
 |
Jennifer E. Van Eyk, Ph.D. |
The mission of the Johns Hopkins Proteomic Innovation Center in Heart Failure is to apply state-of-the-art proteomic methods and develop new approaches and techniques to investigate the biological and clinical aspects of heart failure. Heart failure is a clinical syndrome in which cardiovascular function is insufficient to support the metabolic needs of the body. Many gaps in understanding heart failure remain and it is the goal of this center to identify how heart failure impacts signaling cascades, mitochondria, contractile apparatus, and two new subproteomes (the cell surface and secretory pathway) emphasizing post-translational modifications in order to identify novel ways by which protein modifications either contribute to disease or could be targeted to improve disease outcome. |
Harvard-Broad Proteomics Center |
||
 |
Robert Gerszten, M.D
|
The overall goal of the Center is to establish the infrastructure necessary for the discovery and validation of novel pathways and biomarkers triggered by myocardial ischemia. Our multidisciplinary investigator team contributes expertise in basic science, diagnosis and treatment of acute coronary syndromes, epidemiology and bioinformatics, basic and clinical chemistry, and proteomics. The Center is comprised of a consortium of cooperating institutions, including the Massachusetts General Hospital, Brigham and Women's Hospital, the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Harvard Medical School, the Beth Israel Deaconess Medical Center, and the Broad Institute.
|
Stanford University Proteomics Center |
||
 |
Garry Nolan, Ph.D. |
Pulmonary arterial hypertension (PAH) is a devastating disease that affects over 5,000 Americans. By the time patients display even vague and insidious symptoms such as fatigue and dyspnea, they have much higher PA pressures, which eventually result in right heart failure. Our Center’s approach is a highly interdisciplinary effort to explore and converge results from different, innovative platform technologies that analyze intracellular and secreted proteins related to pulmonary arterial hypertension (PAH) with a continuing development of relational “systems” approaches that allow the integration, comparison and correlation of different datasets generated by diverse technologies developed at the Center. |
UT Health Science Center at San Antonio Cardiovascular Proteomics Center |
||
|
Merry L. Lindsey, Ph.D. |
Our center is dedicated to performing cardiovascular research that involves: 1) Developing multidimensional approaches to examine the mechanisms whereby the left ventricle responds to injury; 2) Applying the knowledge gained to develop therapeutic strategies to prevent, slow, or reverse the progression to heart failure; 3) Disseminating our results to the general, scientific, and medical communities. |
|
|
|
|
University of Texas Medical Branch NHLBI Proteomics Center at Galveston |
||
 |
Alexander Kurosky, Ph.D. |
The UTMB NHLBI Proteomics Center brings the power of multiple analytical technologies to proteomics research focusing on airway inflammation relating to asthma, allergy, and respiratory viruses. The Center consists of seven multidisciplinary teams of scientists and physician-scientists to study protein expression associated with signaling pathways important in lung diseases. In addition, the Center is engaged in the development of innovative technologies for application to proteomics research. The NHLBI proteomics initiative was established to enhance and develop innovative proteomics technologies and apply them to biological questions relevant to heart, lung, blood, and sleep health and disease. |
UCLA Proteomics Center – Global Proteomic Initiative of Cardiovascular Medicine |
||
 |
Peipei Ping, Ph.D. |
The NHLBI Proteomics Center at UCLA consists of an international effort led by UCLA School of Medicine. The central scientific goal aims to provide fundamental information on the proteome biology of cardiovascular diseases, an essential component for the "Human Proteome Initiative". The diverse expertise of our investigator team integrates an array of leading technologies, model systems, and clinical studies for performing global, quantitative, and targeted proteomic analyses, including leveraging the resources offered by the UniProt Project and the Human Protein Atlas. We aim to construct a proteome knowledgebase for the scientific community to empower new discovery in cardiovascular medicine. |
 |
National Heart, Lung, and Blood Institute |  |
National Institutes of Health |  |
Department of Health and Human Services |